


- 44 -

CLAIMS:

1. A compound of Formula (I),




Formula (I)

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;

B is a group of Formula (II):



Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group X is attached to R⁸;

M is -(CH₂)₀₋₂-O-;

R¹ represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-R^a, wherein


R^a represents C₃₋₈cycloalkyl and b is zero or an integer from 1 to 6;

R² represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR³R^{3a}, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo;

R³ and R^{3a} are independently selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;

R⁵ is selected from an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula III-a; III-b; III-c; III-d; III-e; III-f, III-g, III-h, III-i or: III-j;

- 45 -



wherein **het** represents an optionally substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R⁶ and **R**^{6a}, are independently selected from hydrogen and optionally substituted C₁₋₈alkyl; or **R**⁶ and **R**^{6a} together represent carbonyl;

R⁷ represents hydrogen or optionally substituted C₁₋₈alkyl;

or **R**⁶ **A-N-R**⁷ together from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and **R**^{6a} represents hydrogen and optionally substituted C₁₋₈alkyl;

X and **R**⁸ are selected from:

(i) **X** represents N and **R**⁸ is selected from:

cyano, hydrogen, hydroxy, -O-**R**^b, -N**R**^b**R**^c -C(O)O-**R**^b, -CON**R**^b**R**^c or NH-C(O)-**R**^b, where **R**^b and **R**^c are independently selected from hydrogen and C₁₋₄alkyl optionally substituted with hydroxy, amino, N-C₁₋₄alkylamino, N,N-di-C₁₋₄alkylamino, HO-C₂₋₄alkyl-NH- or HO-C₂₋₄alkyl-N(C₁₋₄alkyl)-;

(ii) **X** represents CH and **R**⁸ represents NO₂; and

(iii) **X-R**⁸ represents -O-;

R¹¹ is a group of the formula: N(**R**⁹**R**¹⁰) wherein **R**⁹ represents hydrogen, aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted

- 46 -


C_{1-8} alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8} alkyl; or the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

5 R^{12} and R^{12a} are independently selected from hydrogen or optionally substituted C_{1-8} alkyl; or R^{12} and R^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R^{13} and R^{14} are selected from:

10 (i) R^{13} is selected from hydrogen; optionally substituted C_{1-8} alkyl; optionally substituted aryl; $-R^d-Ar$, where R^d represents C_{1-8} alkylene and Ar represents optionally substituted aryl; and optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R^{14} is selected from hydrogen; optionally substituted C_{1-8} alkyl and optionally substituted aryl;

15 (ii) where R^5 represents a group of formula III-a, III-b or III-i, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

20 (iii) where R^5 represents structure III-e, then the group  represents an optionally substituted 3 to 8 membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

or a salt, pro-drug or solvate thereof.


2. A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8} alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8} alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-8} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0.2})R^b$, $-S(O_{0.2})R^b$, wherein R^b and R^c are as defined in Claim 1.

25


30

- 47 -


3. A compound according to Claim 2 wherein R^9 is a C_{1-6} alkyl group substituted by pyridyl, thienyl, piperidiny, imidazolyl, triazolyl, thiazolyl, pyrrolidiny, piperaziny, morpholiny, imidazoliny, benztriazolyl, benzimidazolyl, pyrimidiny, pyraziny, pyridaziny, oxazolyl, furanyl, pyrroly, 1,3-dioxolanyl or 2-azetiny, each of which is optionally substituted.
4. A compound according to Claim 1 wherein the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.
5. A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from R^{15} wherein R^{15} is selected from optionally substituted aryl, an optionally substituted 3 to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3 to 8 membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined in Claim 1.
6. A compound according to any one of the preceding claims wherein R^5 is selected from a group of formula III-a, III-g, III-h, III-i or III-j:




III-a




III-g



III-h



III-i



III-j

- 48 -

7. A compound according to any one of the preceding claims wherein X and R^8 are selected from

- (a) X represents N and R^8 represents cyano or $-C(O)O-R^b$; or
(b) X represents N and R^8 represents hydrogen.

5

8. A compound according to any one of the preceding claims wherein R^2 is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^eR^f , optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} alkoxy or halo wherein R^e and R^f are independently selected from
10 hydrogen, C_{1-6} alkyl or aryl.

9. A compound according to any one of the preceding claims wherein R^1 is hydrogen.

10. The compound:

- 15 3-[2,2-dimethyl-3-oxo-3-(azabicyclo[2.2.1]heptan-7-yl)propyl]-
4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-yl
carboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrazole;
or a salt, pro-drug or solvate thereof.

- 20 11. A compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 10 for use as a medicament.

12. A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 10 and a pharmaceutically acceptable
25 diluent or carrier.


13. Use of a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 10, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.

30

- 49 -

14. A process of producing a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 10, wherein the process comprises a reaction step selected from any one of steps (a) to (f):-


- (a) for compounds wherein X is N and R⁸ is CN, reaction of a compound of formula XXXII as follows



XXXII

XXXIII


- (b) for compounds wherein X is N and R⁸ is hydrogen, cleavage of the cyano group of compound of formula XXXIII in the presence of acid to produce compound of formula XXXIV



XXXIV

10

- (c) for compounds wherein X is CH and R⁸ is NO₂, reaction of compound of formula XXXV as follows




XXXV


XXXVI

- 50 -


(d) for compounds where $X-R^8$ is O, reaction of compound of formula XXXVII as follows



(e) for compounds where $X-R^8$ is O, reaction of compound of formula XXXIX as follows



(f) to form a compound wherein X is nitrogen reaction of a compound of formula XXXXI as follows



10

and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.